U.S. Markets closed

BioCardia, Inc. (BCDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5900+0.0100 (+0.39%)
At close: 4:00PM EST

BioCardia, Inc.

125 Shoreway Road
Suite B
San Carlos, CA 94070
United States
650 226 0120

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter A. AltmanCEO, Pres & Director362.7kN/A1967
Mr. David McClungChief Financial Officer302.25kN/A1963
Dr. Eric Henricus J. DuckersChief Medical Officer350kN/A1968
Mr. Phil PestaVP of OperationsN/AN/A1966
Dr. Ian McNiece Ph.D.Chief Scientific OfficerN/AN/A1954
Mr. Edward M. GillisSr. VP of DevicesN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.

Corporate Governance

BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.